Nuvectis Pharma Inc (NVCT) Financier

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.